clemastine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihistaminics 671 15686-51-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clemastine
  • meclastine
  • clemastine fumarate
A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
  • Molecular weight: 343.90
  • Formula: C21H26ClNO
  • CLOGP: 5.45
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -5.93
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg O
2 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.39 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 37 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 1977 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Leukopenia 103.21 25.74 75 6304 77215 63405428
Erythema 95.10 25.74 102 6277 175649 63306994
Cytokine release syndrome 81.46 25.74 36 6343 14278 63468365
Toxic epidermal necrolysis 75.61 25.74 41 6338 25293 63457350
General physical health deterioration 67.96 25.74 92 6287 201310 63281333
Hydronephrosis 67.79 25.74 29 6350 10633 63472010
Dyspnoea 66.86 25.74 180 6199 661133 62821510
Tooth erosion 65.66 25.74 14 6365 459 63482184
Allergy test positive 61.89 25.74 14 6365 606 63482037
Pulpitis dental 51.29 25.74 13 6366 915 63481728
Angioedema 49.57 25.74 40 6339 47925 63434718
Sepsis 47.17 25.74 67 6312 153056 63329587
Mucosal inflammation 46.10 25.74 38 6341 46890 63435753
Drug reaction with eosinophilia and systemic symptoms 43.21 25.74 32 6347 33804 63448839
Periodontitis 42.52 25.74 15 6364 3288 63479355
Tachycardia 39.81 25.74 54 6325 118102 63364541
Anaphylactic shock 38.64 25.74 26 6353 23607 63459036
Drug ineffective 37.84 25.74 30 6349 1044735 62437908
Feeling hot 37.82 25.74 35 6344 50319 63432324
Sensory disturbance 37.67 25.74 21 6358 13651 63468992
Stevens-Johnson syndrome 37.37 25.74 26 6353 24924 63457719
Nail toxicity 35.48 25.74 8 6371 341 63482302
Lymphocytosis 33.47 25.74 12 6367 2755 63479888
Circulatory collapse 33.18 25.74 23 6356 21915 63460728
Chills 32.54 25.74 48 6331 113330 63369313
Urticaria 31.15 25.74 58 6321 165744 63316899
Blood lactate dehydrogenase increased 29.82 25.74 22 6357 23094 63459549
Leukocytosis 29.73 25.74 23 6356 25912 63456731
Neutropenia 28.93 25.74 58 6321 174947 63307696
Venous thrombosis limb 28.85 25.74 11 6368 2997 63479646
Thrombocytopenia 28.54 25.74 53 6326 151104 63331539
Febrile neutropenia 28.19 25.74 46 6333 118403 63364240
Lymphangiectasia 27.24 25.74 5 6374 74 63482569
Polyneuropathy 26.15 25.74 17 6362 14572 63468071

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 80.45 23.77 43 3930 22834 34930124
Pyrexia 63.16 23.77 125 3848 332888 34620070
Pulpitis dental 50.09 23.77 12 3961 590 34952368
Toxic epidermal necrolysis 47.59 23.77 30 3943 21616 34931342
Chills 42.31 23.77 49 3924 80994 34871964
Leukopenia 41.49 23.77 43 3930 62813 34890145
Febrile neutropenia 38.18 23.77 61 3912 136788 34816170
SARS-CoV-2 sepsis 36.04 23.77 7 3966 125 34952833
Long QT syndrome 31.88 23.77 12 3961 2791 34950167
Mantle cell lymphoma stage III 31.46 23.77 5 3968 25 34952933
Lacrimal duct neoplasm 31.46 23.77 5 3968 25 34952933
Conjunctivitis 30.63 23.77 17 3956 9688 34943270
Drug therapeutic incompatibility 30.44 23.77 6 3967 116 34952842
Herpes zoster reactivation 30.24 23.77 7 3966 296 34952662
Guillain-Barre syndrome 28.82 23.77 14 3959 6073 34946885
Polyneuropathy 28.67 23.77 19 3954 14877 34938081
Fibrin D dimer increased 27.07 23.77 12 3961 4232 34948726
Drug reaction with eosinophilia and systemic symptoms 26.22 23.77 25 3948 32987 34919971
Cancer fatigue 26.20 23.77 5 3968 81 34952877
Neutropenia 26.13 23.77 56 3917 156722 34796236
Infusion related reaction 25.86 23.77 31 3942 53026 34899932

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Leukopenia 124.60 21.16 107 9523 116406 79618352
Toxic epidermal necrolysis 112.60 21.16 69 9561 44512 79690246
Cytokine release syndrome 109.96 21.16 63 9567 35935 79698823
Pulpitis dental 101.70 21.16 25 9605 1288 79733470
Erythema 100.43 21.16 129 9501 223161 79511597
Pyrexia 63.84 21.16 203 9427 678506 79056252
Chills 61.86 21.16 86 9544 160148 79574610
General physical health deterioration 61.33 21.16 115 9515 275123 79459635
Tooth erosion 59.54 21.16 13 9617 395 79734363
Drug reaction with eosinophilia and systemic symptoms 58.64 21.16 54 9576 64190 79670568
Allergy test positive 57.08 21.16 14 9616 714 79734044
Angioedema 56.37 21.16 57 9573 75978 79658780
Periodontitis 56.33 21.16 21 9609 4475 79730283
Polyneuropathy 52.47 21.16 34 9596 24117 79710641
Stevens-Johnson syndrome 50.20 21.16 40 9590 39126 79695632
Hydronephrosis 49.17 21.16 29 9601 17425 79717333
Febrile neutropenia 47.10 21.16 93 9537 230906 79503852
Lymphocytosis 44.83 21.16 18 9612 4675 79730083
Anaphylactic shock 44.51 21.16 36 9594 35960 79698798
Dyspnoea 44.13 21.16 212 9418 856813 78877945
Sepsis 43.93 21.16 99 9531 269329 79465429
Circulatory collapse 43.07 21.16 36 9594 37632 79697126
Neutropenia 41.75 21.16 101 9529 287609 79447149
Feeling hot 39.27 21.16 42 9588 59692 79675066
Tachycardia 39.19 21.16 74 9556 177694 79557064
Conjunctivitis 38.93 21.16 29 9601 25686 79709072
Tumour lysis syndrome 36.25 21.16 27 9603 23912 79710846
SARS-CoV-2 sepsis 35.40 21.16 7 9623 129 79734629
Anaemia 34.53 21.16 125 9505 444890 79289868
Mucosal erosion 33.39 21.16 12 9618 2306 79732452
Sensory disturbance 32.19 21.16 21 9609 15056 79719702
Venous thrombosis limb 32.17 21.16 14 9616 4443 79730315
Leukocytosis 31.14 21.16 32 9598 43423 79691335
Bronchospasm 31.02 21.16 25 9605 24834 79709924
Guillain-Barre syndrome 30.91 21.16 17 9613 8948 79725810
Thrombocytopenia 30.13 21.16 85 9545 265174 79469584
Urticaria 30.09 21.16 68 9562 185133 79549625
C-reactive protein increased 28.78 21.16 54 9576 128973 79605785
Nail toxicity 28.56 21.16 7 9623 356 79734402
Blood lactate dehydrogenase increased 28.35 21.16 29 9601 39141 79695617
Drug therapeutic incompatibility 28.09 21.16 6 9624 164 79734594
Infusion related reaction 27.34 21.16 75 9555 230162 79504596
Lymphangiectasia 24.49 21.16 5 9625 109 79734649
Tryptase increased 24.48 21.16 7 9623 646 79734112
Arthralgia 24.40 21.16 20 9610 571783 79162975
Mucosal inflammation 23.96 21.16 37 9593 75543 79659215
Fibrin D dimer increased 23.38 21.16 14 9616 8640 79726118
Torsade de pointes 23.20 21.16 19 9611 19293 79715465
B-lymphocyte count decreased 22.95 21.16 8 9622 1406 79733352
Pain 22.88 21.16 31 9599 703771 79030987
Long QT syndrome 22.50 21.16 12 9618 5943 79728815
Neisseria infection 22.38 21.16 5 9625 169 79734589
Electrocardiogram T wave biphasic 22.08 21.16 5 9625 180 79734578

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D04AA14 DERMATOLOGICALS
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
Antihistamines for topical use
ATC R06AA04 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Aminoalkyl ethers
ATC R06AA54 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Aminoalkyl ethers
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:50857 anti-allergic drugs
CHEBI has role CHEBI:59683 antipruritic drugs
MeSH PA D018926 Anti-Allergic Agents
MeSH PA D000982 Antipruritics
MeSH PA D003879 Dermatologic Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Urticaria indication 126485001
Itching of skin indication 418363000
Allergic conjunctivitis indication 473460002 DOID:11204
Anaphylaxis Adjunct indication
Ocular hypertension contraindication 4210003 DOID:9282
Peptic ulcer contraindication 13200003 DOID:750
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Chronic idiopathic constipation contraindication 82934008
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.7 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 8.59 WOMBAT-PK CHEMBL
D(1A) dopamine receptor GPCR Ki 6.12 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 7.35 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 7.16 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.85 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 7.92 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.51 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 8.04 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.64 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.28 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 7.44 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.85 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 8.60 DRUG MATRIX
Histamine H2 receptor GPCR Ki 6.44 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 7.80 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 8.08 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 8.56 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 8.22 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 7.85 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.27 DRUG MATRIX
Cytochrome P450 2D6 Enzyme Ki 5.70 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.82 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 6.22 DRUG MATRIX
Solute carrier family 22 member 1 Transporter IC50 5.31 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 6.70 WOMBAT-PK
Transmembrane protein 97 Enzyme Ki 7.60 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 7.39 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 6.66 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.35 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 7.28 CHEMBL

External reference:

IDSource
4019681 VUID
N0000147773 NUI
D00666 KEGG_DRUG
14976-57-9 SECONDARY_CAS_RN
142430 RXNORM
4018759 VANDF
4019681 VANDF
C0008929 UMLSCUI
CHEBI:3738 CHEBI
CHEMBL1626 ChEMBL_ID
DB00283 DRUGBANK_ID
CHEMBL1200795 ChEMBL_ID
D002974 MESH_DESCRIPTOR_UI
26987 PUBCHEM_CID
6063 IUPHAR_LIGAND_ID
2231 INN_ID
95QN29S1ID UNII
224 MMSL
4464 MMSL
d00780 MMSL
003410 NDDF
004441 NDDF
372744005 SNOMEDCT_US
45218006 SNOMEDCT_US
83968007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clemastine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0308 TABLET 2.68 mg ORAL ANDA 13 sections
Clemastine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0308 TABLET 2.68 mg ORAL ANDA 13 sections
Clemastine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 51655-425 TABLET 2.68 mg Oral ANDA 12 sections
Clemastine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 54838-514 SYRUP 0.67 mg ORAL ANDA 17 sections
Clemastine Fumarate HUMAN OTC DRUG LABEL 1 54868-5913 TABLET 1.34 mg ORAL ANDA 14 sections
CLEMASTINE FUMARATE HUMAN PRESCRIPTION DRUG LABEL 1 62135-713 SYRUP 0.67 mg ORAL ANDA 12 sections
Clemastine Fumarate HUMAN OTC DRUG LABEL 1 68151-2456 TABLET 1.34 mg ORAL ANDA 14 sections
Clemastine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 73308-358 SYRUP 0.67 mg ORAL ANDA 17 sections
Clemastine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 73308-358 SYRUP 0.67 mg ORAL ANDA 17 sections